Kirkland – In partnership with Sumitomo Pharma Canada, Inc., Pfizer Canada ULC is proud to announce that supply of MYFEMBREE® (relugolix 40 mg, estradiol 1 mg and norethindrone acetate tablets 0.5 mg tablets) is now available in Canada by prescription for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, as well as for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.[1]
“For many fibroid and endometriosis patients, symptoms can be debilitating. These conditions progress for years, while women are simultaneously managing jobs and families,” said Patricia Lee, Founder of CANFib (Canadian Women with Fibroids). “MYFEMBREE being added to Canada’s toolbox means women with endometriosis and uterine fibroids have much-needed access to new treatment options for their symptoms.”
“The introduction of MYFEMBREE represents a significant advance in the care of pre-menopausal patients battling with endometriosis and uterine fibroids,” said Dr. Jamie Kroft, Deputy Chief, Obstetrics & Gynaecology – Minimally Invasive Gynaecologic Surgery at Sunnybrook Health Sciences Centre and Associate Professor, at the University of Toronto. “Providing new options for managing these conditions is a positive step forward in supporting patients’ well-being and offering renewed optimism in their treatment journey.”
As previously announced, Pfizer Canada ULC will lead commercialization efforts of MYFEMBREE for both the uterine fibroid and endometriosis indications in Canada.